Over 26 weeks, the complement C5 inhibitor gefurulimab showed its ability to produce statistically significant improvements in Myasthenia Gravis Activities of Daily Living (MG-ADL) total score, a clinically meaningful result, as well as reduce…
Gefurulimab for MG Exhibits Lasting Efficacy, Safety in Topline PREVAIL Trial Data
